Jianhua Zhao, Jacquelyn Reuther, Kaylee Scozzaro, Megan Hawley, Emily Metzger, Matthew Emery, Ingrid Chen, Michelle Barbosa, Laura Johnson, Alijah O'Connor, Mike Washburn, Luke Hartje, Erik Reckase, Verity Johnson, Yuhua Zhang, Emily Westheimer, William O'Callaghan, Nirav Malani, Adrian Chesh, Michael Moreau, Robert Daber
BACKGROUND: Highly sensitive molecular assays have been developed to detect plasma-based circulating tumor DNA (ctDNA), and emerging evidence suggests their clinical utility for monitoring minimal residual disease and recurrent disease, providing prognostic information, and monitoring therapy responses in patients with solid tumors. The Invitae Personalized Cancer Monitoring™ assay uses a patient-specific, tumor-informed variant signature identified through whole exome sequencing to detect ctDNA in peripheral blood of patients with solid tumors...
August 26, 2023: Molecular Diagnosis & Therapy